ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adalimumab Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-31O10247
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global and United States Adalimumab Market Report Forecast 2022 2028
BUY CHAPTERS

Global Adalimumab Market Research Report 2025

Code: QYRE-Auto-31O10247
Report
September 2025
Pages:82
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AbbVie
Amgen Inc
Sandoz Inc
Boehringer Ingelheim
Mylan NV
Biogen
Aark Pharmaceuticals
Delphis Pharma
Amgevita

Adalimumab Market Size

The global market for Adalimumab was valued at US$ 154 million in the year 2024 and is projected to reach a revised size of US$ 209 million by 2031, growing at a CAGR of 4.5% during the forecast period.

Adalimumab Market

Adalimumab Market

Adalimumab, sold under the trade name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn"s disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis.
Adalimumab is a widely used biologic medication that belongs to the class of tumor necrosis factor (TNF) inhibitors. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn"s disease, and ulcerative colitis. Autoimmune diseases are on the rise globally, affecting millions of people. Adalimumab is one of the leading treatment options for these conditions, driving the demand for the medication. Improved awareness and diagnosis of autoimmune diseases have led to an increased demand for effective treatment options like adalimumab. Biologic drugs, including adalimumab, have gained popularity due to their targeted treatment approach and potential for better disease management. Patients are increasingly opting for these medications over conventional therapies, driving the market growth of adalimumab. Adalimumab has received approvals for an expanding range of indications, including pediatric use and additional inflammatory conditions. The availability of more indications and treatment options has expanded the addressable market for adalimumab. The expiration of adalimumab"s patent in various regions has opened the doors for the entry of biosimilar versions of the drug. Biosimilars offer competitive pricing, increasing market accessibility and potentially driving the overall market growth. Reimbursement policies and insurance coverage play a significant role in the adoption and market drive of adalimumab. Favorable policies and coverage encourage patient access and contribute to the growth of the market. Advances in drug delivery systems, such as autoinjectors and pre-filled syringes, have increased the convenience and ease of administration for patients using adalimumab, enhancing its market drive.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Adalimumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab.
The Adalimumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Adalimumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adalimumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Adalimumab Market Report

Report Metric Details
Report Name Adalimumab Market
Accounted market size in year US$ 154 million
Forecasted market size in 2031 US$ 209 million
CAGR 4.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Adults
  • Children
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AbbVie, Amgen, Sandoz, Boehringer Ingelheim, Mylan, Biogen, Aark Pharmaceuticals, Amgevita, Delphis Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Adalimumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Adalimumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Adalimumab Market growing?

Ans: The Adalimumab Market witnessing a CAGR of 4.5% during the forecast period 2025-2031.

What is the Adalimumab Market size in 2031?

Ans: The Adalimumab Market size in 2031 will be US$ 209 million.

Who are the main players in the Adalimumab Market report?

Ans: The main players in the Adalimumab Market are AbbVie, Amgen, Sandoz, Boehringer Ingelheim, Mylan, Biogen, Aark Pharmaceuticals, Amgevita, Delphis Pharma

What are the Application segmentation covered in the Adalimumab Market report?

Ans: The Applications covered in the Adalimumab Market report are Adults, Children

What are the Type segmentation covered in the Adalimumab Market report?

Ans: The Types covered in the Adalimumab Market report are Adalimumab, Adalimumab Biosimilar

Recommended Reports

Biosimilar and Biologics

Autoimmune & Inflammatory

Rheumatology & Arthritis

1 Adalimumab Market Overview
1.1 Product Definition
1.2 Adalimumab by Type
1.2.1 Global Adalimumab Market Value Comparison by Type (2024 VS 2031)
1.2.2 Adalimumab
1.2.3 Adalimumab Biosimilar
1.3 Adalimumab by Application
1.3.1 Global Adalimumab Market Value by Application (2024 VS 2031)
1.3.2 Adults
1.3.3 Children
1.4 Global Adalimumab Market Size Estimates and Forecasts
1.4.1 Global Adalimumab Revenue 2020-2031
1.4.2 Global Adalimumab Sales 2020-2031
1.4.3 Global Adalimumab Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Adalimumab Market Competition by Manufacturers
2.1 Global Adalimumab Sales Market Share by Manufacturers (2020-2025)
2.2 Global Adalimumab Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Adalimumab Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Adalimumab, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Adalimumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab, Product Type & Application
2.7 Global Key Manufacturers of Adalimumab, Date of Enter into This Industry
2.8 Global Adalimumab Market Competitive Situation and Trends
2.8.1 Global Adalimumab Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Adalimumab Players Market Share by Revenue
2.8.3 Global Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Adalimumab Market Scenario by Region
3.1 Global Adalimumab Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Adalimumab Sales by Region: 2020-2031
3.2.1 Global Adalimumab Sales by Region: 2020-2025
3.2.2 Global Adalimumab Sales by Region: 2026-2031
3.3 Global Adalimumab Revenue by Region: 2020-2031
3.3.1 Global Adalimumab Revenue by Region: 2020-2025
3.3.2 Global Adalimumab Revenue by Region: 2026-2031
3.4 North America Adalimumab Market Facts & Figures by Country
3.4.1 North America Adalimumab Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Adalimumab Sales by Country (2020-2031)
3.4.3 North America Adalimumab Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Adalimumab Market Facts & Figures by Country
3.5.1 Europe Adalimumab Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Adalimumab Sales by Country (2020-2031)
3.5.3 Europe Adalimumab Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab Market Facts & Figures by Region
3.6.1 Asia Pacific Adalimumab Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Adalimumab Sales by Region (2020-2031)
3.6.3 Asia Pacific Adalimumab Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Adalimumab Market Facts & Figures by Country
3.7.1 Latin America Adalimumab Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Adalimumab Sales by Country (2020-2031)
3.7.3 Latin America Adalimumab Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adalimumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Adalimumab Sales by Country (2020-2031)
3.8.3 Middle East and Africa Adalimumab Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Adalimumab Sales by Type (2020-2031)
4.1.1 Global Adalimumab Sales by Type (2020-2025)
4.1.2 Global Adalimumab Sales by Type (2026-2031)
4.1.3 Global Adalimumab Sales Market Share by Type (2020-2031)
4.2 Global Adalimumab Revenue by Type (2020-2031)
4.2.1 Global Adalimumab Revenue by Type (2020-2025)
4.2.2 Global Adalimumab Revenue by Type (2026-2031)
4.2.3 Global Adalimumab Revenue Market Share by Type (2020-2031)
4.3 Global Adalimumab Price by Type (2020-2031)
5 Segment by Application
5.1 Global Adalimumab Sales by Application (2020-2031)
5.1.1 Global Adalimumab Sales by Application (2020-2025)
5.1.2 Global Adalimumab Sales by Application (2026-2031)
5.1.3 Global Adalimumab Sales Market Share by Application (2020-2031)
5.2 Global Adalimumab Revenue by Application (2020-2031)
5.2.1 Global Adalimumab Revenue by Application (2020-2025)
5.2.2 Global Adalimumab Revenue by Application (2026-2031)
5.2.3 Global Adalimumab Revenue Market Share by Application (2020-2031)
5.3 Global Adalimumab Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbbVie Adalimumab Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Company Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Amgen Adalimumab Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Sandoz
6.3.1 Sandoz Company Information
6.3.2 Sandoz Description and Business Overview
6.3.3 Sandoz Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sandoz Adalimumab Product Portfolio
6.3.5 Sandoz Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Company Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Boehringer Ingelheim Adalimumab Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Mylan
6.5.1 Mylan Company Information
6.5.2 Mylan Description and Business Overview
6.5.3 Mylan Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Mylan Adalimumab Product Portfolio
6.5.5 Mylan Recent Developments/Updates
6.6 Biogen
6.6.1 Biogen Company Information
6.6.2 Biogen Description and Business Overview
6.6.3 Biogen Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Biogen Adalimumab Product Portfolio
6.6.5 Biogen Recent Developments/Updates
6.7 Aark Pharmaceuticals
6.7.1 Aark Pharmaceuticals Company Information
6.7.2 Aark Pharmaceuticals Description and Business Overview
6.7.3 Aark Pharmaceuticals Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Aark Pharmaceuticals Adalimumab Product Portfolio
6.7.5 Aark Pharmaceuticals Recent Developments/Updates
6.8 Amgevita
6.8.1 Amgevita Company Information
6.8.2 Amgevita Description and Business Overview
6.8.3 Amgevita Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Amgevita Adalimumab Product Portfolio
6.8.5 Amgevita Recent Developments/Updates
6.9 Delphis Pharma
6.9.1 Delphis Pharma Company Information
6.9.2 Delphis Pharma Description and Business Overview
6.9.3 Delphis Pharma Adalimumab Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Delphis Pharma Adalimumab Product Portfolio
6.9.5 Delphis Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab Industry Chain Analysis
7.2 Adalimumab Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab Production Mode & Process Analysis
7.4 Adalimumab Sales and Marketing
7.4.1 Adalimumab Sales Channels
7.4.2 Adalimumab Distributors
7.5 Adalimumab Customer Analysis
8 Adalimumab Market Dynamics
8.1 Adalimumab Industry Trends
8.2 Adalimumab Market Drivers
8.3 Adalimumab Market Challenges
8.4 Adalimumab Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
AbbVie
Amgen Inc
Sandoz Inc
Boehringer Ingelheim
Mylan NV
Biogen
Aark Pharmaceuticals
Delphis Pharma
Amgevita
List of Tables
 Table 1. Global Adalimumab Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Adalimumab Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Adalimumab Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Adalimumab Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Adalimumab Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Adalimumab Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Adalimumab Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Adalimumab Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Adalimumab, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Adalimumab, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Adalimumab, Product Type & Application
 Table 12. Global Key Manufacturers of Adalimumab, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Adalimumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Adalimumab Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Adalimumab Sales by Region (2020-2025) & (K Units)
 Table 18. Global Adalimumab Sales Market Share by Region (2020-2025)
 Table 19. Global Adalimumab Sales by Region (2026-2031) & (K Units)
 Table 20. Global Adalimumab Sales Market Share by Region (2026-2031)
 Table 21. Global Adalimumab Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Adalimumab Revenue Market Share by Region (2020-2025)
 Table 23. Global Adalimumab Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Adalimumab Revenue Market Share by Region (2026-2031)
 Table 25. North America Adalimumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Adalimumab Sales by Country (2020-2025) & (K Units)
 Table 27. North America Adalimumab Sales by Country (2026-2031) & (K Units)
 Table 28. North America Adalimumab Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Adalimumab Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Adalimumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Adalimumab Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Adalimumab Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Adalimumab Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Adalimumab Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Adalimumab Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Adalimumab Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Adalimumab Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Adalimumab Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Adalimumab Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Adalimumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Adalimumab Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Adalimumab Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Adalimumab Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Adalimumab Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Adalimumab Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Adalimumab Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Adalimumab Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Adalimumab Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Adalimumab Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Adalimumab Sales (K Units) by Type (2020-2025)
 Table 51. Global Adalimumab Sales (K Units) by Type (2026-2031)
 Table 52. Global Adalimumab Sales Market Share by Type (2020-2025)
 Table 53. Global Adalimumab Sales Market Share by Type (2026-2031)
 Table 54. Global Adalimumab Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Adalimumab Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Adalimumab Revenue Market Share by Type (2020-2025)
 Table 57. Global Adalimumab Revenue Market Share by Type (2026-2031)
 Table 58. Global Adalimumab Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Adalimumab Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Adalimumab Sales (K Units) by Application (2020-2025)
 Table 61. Global Adalimumab Sales (K Units) by Application (2026-2031)
 Table 62. Global Adalimumab Sales Market Share by Application (2020-2025)
 Table 63. Global Adalimumab Sales Market Share by Application (2026-2031)
 Table 64. Global Adalimumab Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Adalimumab Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Adalimumab Revenue Market Share by Application (2020-2025)
 Table 67. Global Adalimumab Revenue Market Share by Application (2026-2031)
 Table 68. Global Adalimumab Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Adalimumab Price (USD/Unit) by Application (2026-2031)
 Table 70. AbbVie Company Information
 Table 71. AbbVie Description and Business Overview
 Table 72. AbbVie Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. AbbVie Adalimumab Product
 Table 74. AbbVie Recent Developments/Updates
 Table 75. Amgen Company Information
 Table 76. Amgen Description and Business Overview
 Table 77. Amgen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Amgen Adalimumab Product
 Table 79. Amgen Recent Developments/Updates
 Table 80. Sandoz Company Information
 Table 81. Sandoz Description and Business Overview
 Table 82. Sandoz Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Sandoz Adalimumab Product
 Table 84. Sandoz Recent Developments/Updates
 Table 85. Boehringer Ingelheim Company Information
 Table 86. Boehringer Ingelheim Description and Business Overview
 Table 87. Boehringer Ingelheim Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Boehringer Ingelheim Adalimumab Product
 Table 89. Boehringer Ingelheim Recent Developments/Updates
 Table 90. Mylan Company Information
 Table 91. Mylan Description and Business Overview
 Table 92. Mylan Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Mylan Adalimumab Product
 Table 94. Mylan Recent Developments/Updates
 Table 95. Biogen Company Information
 Table 96. Biogen Description and Business Overview
 Table 97. Biogen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Biogen Adalimumab Product
 Table 99. Biogen Recent Developments/Updates
 Table 100. Aark Pharmaceuticals Company Information
 Table 101. Aark Pharmaceuticals Description and Business Overview
 Table 102. Aark Pharmaceuticals Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Aark Pharmaceuticals Adalimumab Product
 Table 104. Aark Pharmaceuticals Recent Developments/Updates
 Table 105. Amgevita Company Information
 Table 106. Amgevita Description and Business Overview
 Table 107. Amgevita Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Amgevita Adalimumab Product
 Table 109. Amgevita Recent Developments/Updates
 Table 110. Delphis Pharma Company Information
 Table 111. Delphis Pharma Description and Business Overview
 Table 112. Delphis Pharma Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Delphis Pharma Adalimumab Product
 Table 114. Delphis Pharma Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. Adalimumab Distributors List
 Table 118. Adalimumab Customers List
 Table 119. Adalimumab Market Trends
 Table 120. Adalimumab Market Drivers
 Table 121. Adalimumab Market Challenges
 Table 122. Adalimumab Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Adalimumab
 Figure 2. Global Adalimumab Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Adalimumab Market Share by Type: 2024 & 2031
 Figure 4. Adalimumab Product Picture
 Figure 5. Adalimumab Biosimilar Product Picture
 Figure 6. Global Adalimumab Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Adalimumab Market Share by Application: 2024 & 2031
 Figure 8. Adults
 Figure 9. Children
 Figure 10. Global Adalimumab Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Adalimumab Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Adalimumab Sales (2020-2031) & (K Units)
 Figure 13. Global Adalimumab Average Price (USD/Unit) & (2020-2031)
 Figure 14. Adalimumab Report Years Considered
 Figure 15. Adalimumab Sales Share by Manufacturers in 2024
 Figure 16. Global Adalimumab Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Adalimumab Players: Market Share by Revenue in Adalimumab in 2024
 Figure 18. Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Adalimumab Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Adalimumab Sales Market Share by Country (2020-2031)
 Figure 21. North America Adalimumab Revenue Market Share by Country (2020-2031)
 Figure 22. U.S. Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Adalimumab Sales Market Share by Country (2020-2031)
 Figure 25. Europe Adalimumab Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Adalimumab Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Adalimumab Revenue Market Share by Region (2020-2031)
 Figure 33. China Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Taiwan Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Philippines Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Adalimumab Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Adalimumab Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Adalimumab Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Adalimumab Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. U.A.E Adalimumab Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Adalimumab by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Adalimumab by Type (2020-2031)
 Figure 55. Global Adalimumab Price (USD/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Adalimumab by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Adalimumab by Application (2020-2031)
 Figure 58. Global Adalimumab Price (USD/Unit) by Application (2020-2031)
 Figure 59. Adalimumab Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Adalimumab Drug Market Research Report 2024
Global Humira Market Insights Forecast to 2030
Adalimumab Humira and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Humira Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global TNF Inhibitors for the Treatment of Rheumatoid Arthritis Market Research Report 2024
Global Tumor Necrosis Factor Alpha Inhibitors Market Research Report 2024
Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Tumor Necrosis Factor TNF Antagonists Market Research Report 2024
Global Adalimumab Infliximab And Etanercept Biosimilars Market Research Report 2024
Global Anti TNF α Monoclonal Antibody Market Insights Forecast to 2030
Remicade infliximab Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adalimumab Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ustekinumab Biosimilars Market Research Report 2024
Global Tumor Necrosis Factor TNF Inhibitor Drugs Market Insights Forecast to 2030
Anti inflammatory Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Rheumatoid Arthritis RA Medications Market Research Report 2025
Global Mesalamine Market Research Report 2024
Global Anti inflammatory Therapeutics Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030
Interchangeable Biosimilar Humira Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions